NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 20. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ONO KOJI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-20, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 |
|---|
| Patentnummer: |
US2023117295 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01694058X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01694058X | ||
| 003 | DE-627 | ||
| 005 | 20240126101113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01694058X | ||
| 035 | |a (EPA)US2023117295 | ||
| 035 | |a (EPA)68060186 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ONO KOJI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-20, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 | ||
| 520 | |a Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ITO MASAHIRO |4 aut | |
| 700 | 0 | |a TANAKA TOSHIO |4 aut | |
| 700 | 0 | |a ASANO MORITERU |4 aut | |
| 700 | 0 | |a HIRAYAMA TAKAHARU |4 aut | |
| 700 | 0 | |a FUJIMOTO JUN |4 aut | |
| 700 | 0 | |a SAKAUCHI NOBUKI |4 aut | |
| 700 | 0 | |a HIRATA YASUHIRO |4 aut | |
| 700 | 0 | |a TOITA AKINORI |4 aut | |
| 700 | 0 | |a MORISHITA NAO |4 aut | |
| 700 | 0 | |a KOKUBO HIRONORI |4 aut | |
| 700 | 0 | |a IMAEDA YASUHIRO |4 aut | |
| 700 | 0 | |a MAEZAKI HIRONOBU |4 aut | |
| 700 | 0 | |a CARY DOUGLAS ROBERT |4 aut | |
| 700 | 0 | |a MIZOJIRI RYO |4 aut | |
| 700 | 0 | |a CHO NOBUO |4 aut | |
| 700 | 0 | |a BANNO HIROSHI |4 aut | |
| 700 | 0 | |a TOKUHARA HIDEKAZU |4 aut | |
| 700 | 0 | |a ARIKAWA YASUYOSHI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 20. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:20 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/68060186/publication/US2023117295A1?q=US2023117295 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 20 |c 04 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 20 |c 04 | ||